MediWound Ltd. announced on September 2, 2025, that its enzymatic burn debridement therapy, NexoBrid, would be featured in 36 scientific oral and poster presentations at the 21st European Burns Association (EBA) Congress. The congress took place from September 3-6, 2025, in Berlin, Germany.
Leading burn specialists from across Europe presented data on pediatric, elderly, and critically burned patients, demonstrating NexoBrid's consistent benefits in survival, recovery, and scar outcomes. The presentations also highlighted its value in infection control and modulation of systemic inflammatory responses.
Comparative and long-term studies further supported NexoBrid’s superiority over surgical excision, reaffirming its role in both routine care and mass casualty scenarios. This extensive scientific spotlight reflects the growing real-world experience and clinical data supporting NexoBrid as an important therapy in advancing burn care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.